BioNTech on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its experimental cancer drug.
Tag Archive for: antibody-drug conjugate (ADC)
After a brief market exit in November 2022, GSK appears to be giving its multiple myeloma treatment Blenrep a second chance, with company executives touting its “multi-blockbuster” potential in a virtual oncology-focused investor event on Monday.
AstraZeneca and Daiichi Sankyo on Monday revealed additional data from the Phase III TROPION-Lung01 study, showing that their investigational antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) failed to significantly improve overall survival in non-small cell lung cancer patients.
Los Angeles-based startup TORL BioTherapeutics on Wednesday closed a $158 million oversubscribed Series B-2 funding round, which will go toward the advancement of its pipeline of novel antibody-drug conjugates for oncology.
Merck has bought biotech startup Abceutics in a bid to develop safer antibody-drug conjugates and minimize their off-target effects on healthy cells, according to a Friday announcement from the University at Buffalo, whose laboratory created the spin-off company.
Genmab on Wednesday announced that it will acquire the privately owned biotech ProfoundBio for $1.8 billion in cash. The deal is meant to help the Danish pharma deepen its cancer pipeline with next-generation antibody-drug conjugate therapies.
Interim data from the Phase III innovaTV 301 trial showed that Genmab and Seagen’s antibody-drug conjugate Tivdak (tisotumab vedotin-tftv) met its primary endpoint, leading to significant survival benefit in patients with metastatic cervical cancer, the companies announced Monday.
BioNTech’s licensed antibody-drug conjugate is moving on to Phase III testing in a potential effort to challenge AstraZeneca and Daiichi Sankyo’s blockbuster Enhertu in a heavily treated breast cancer subpopulation. DualityBio, BioNTech’s partner and the ADC’s creator, posted the trial plans Wednesday.
Under a new collaborative research agreement, Astellas Pharma is turning to an interesting choice of partner to develop a novel antibody-drug conjugate platform for oncology therapeutics. Tuesday, the Tokyo-based biopharma announced a collaboration with tech giant Sony Corporation.
Following its failed deal with Merck last year, Seagen has a new suitor. The Seattle-based company is in talks with Pfizer over a potential acquisition, The Wall Street Journal reported Sunday evening, citing people familiar with the matter.